Victory Over a Silent Surgical Menace: D-PLEX₁₀₀ Slashes Infection Rates!
- PolyPid's D-PLEX₁₀₀ achieved a stunning 58% reduction in surgical site infections (SSIs) in its Phase 3 SHIELD II trial4, 5.
- The groundbreaking drug successfully met all primary and key secondary endpoints, offering new hope against a common and costly surgical complication.
- With FDA Fast Track and Breakthrough Therapy designations, D-PLEX₁₀₀ is poised to revolutionize post-operative care.
In the high-stakes world of abdominal surgery, a hidden enemy often sabotages healing: the surgical site infection (SSI). These infections are a grim reality, impacting nearly one in four high-risk colorectal surgery patients, prolonging agony, and costing the U.S. healthcare system billions annually1, 2, 3. But now, a beacon of hope emerges.
PolyPid has announced electrifying topline results from its pivotal SHIELD II Phase 3 trial. Their innovative D-PLEX₁₀₀, a locally administered antibiotic, has demonstrated a powerful ability to protect patients. The trial, focusing on abdominal colorectal surgeries with large incisions, revealed that D-PLEX₁₀₀ dramatically reduced SSIs by an incredible 58% compared to standard care alone4, 5—slashing the rate from 9.5% down to a mere 3.8%.
"These positive results provide clear and compelling evidence of D-PLEX₁₀₀’s ability to significantly reduce SSIs," declared Dikla Czaczkes Akselbrad, CEO of PolyPid. Experts like Dr. Charles E. Edmiston, Jr. anticipate D-PLEX₁₀₀ "will be rapidly embraced as a critical component" in surgical care.
This isn't just a win; it's a paradigm shift. D-PLEX₁₀₀, with its unique PLEX technology ensuring prolonged drug release directly at the surgical site, promises to reduce suffering, shorten hospital stays, and cut overwhelming healthcare costs. Targeting over 12 million annual U.S. surgeries, PolyPid is on track for an NDA submission in early 2026, heralding a new dawn in surgical recovery.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.